Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.
Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.
MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.
The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.
In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.
MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.
MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.
Latest shares articles
Ratings and Reviews
Ratings and Reviews
